Hydrogenology
Source-linked study record

Using oral molecular hydrogen supplements to combat microinflammation in humans: a pilot observational study

Lu KC, Shen MC, Wang RL, Chen WW, Chiu SH, Kao YH, Liu FC, Hsiao PJ. · International journal of medical sciences. 2024;21(12):2390-2401.

HumanH₂-rich waterPublished 2024Source checked
Study record, not medical adviceThis record reports what the source states. It is not medical advice and does not establish that molecular hydrogen is effective, safe or appropriate for any person.
Quick summary

Study at a glance

Evidence type

Human

Population or model

Thirty adults with chronic stable inflammatory/metabolic conditions recruited from an outpatient department.

Intervention and dose

Oral solid H₂ capsules for 28 days: low dose 1 capsule each morning; medium dose 3 capsules each morning; high dose 3 capsules morning and 3 evening. · The clinical intervention used capsules, not H₂-rich water. The article separately prepared 1,200 ppb H₂-rich water for an in-vitro comparison; that concentration was not the participants’ administered dose.

Duration

28 days (4 weeks).

Reported result

Article-reported result excerpt (24 words maximum): “Results: Compared to HRW and CaH_2, OSHCs demonstrated a prolonged reduction in ORP for 60 minutes in vitro and enabled a regulated release of…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.

Main limitation

Human evidence; design, sample size and comparator limit interpretation. Funding or grant information is reported in the full article. The article declares no conflicts of interest.

Evidence and classification

What kind of evidence is this?

Evidence type

Human

Reported design

Human interventional or observational study

Research topic

Oral and dental health

Administration form

H₂-rich water

Information not yet classified

Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.

Reported in the source

Methods

Population or model

Thirty adults with chronic stable inflammatory/metabolic conditions recruited from an outpatient department.

Sample

30 participants; low-, medium- and high-dose groups of 10 participants each.

Duration

28 days (4 weeks).

Intervention

Oral solid H₂ capsules for 28 days: low dose 1 capsule each morning; medium dose 3 capsules each morning; high dose 3 capsules morning and 3 evening.

Hydrogen form

H₂ dissolved in drinking water plus an oral H₂-generating preparation — H₂ only unless the full text explicitly reports oxygen co-delivery.

Dose or H₂ specification

The clinical intervention used capsules, not H₂-rich water. The article separately prepared 1,200 ppb H₂-rich water for an in-vitro comparison; that concentration was not the participants’ administered dose.

Comparator

Three non-randomized capsule-dose groups; the laboratory comparison also examined H₂-rich water and calcium hydride.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

survival or mortality, clinical symptoms or functional scores, tumor growth or cancer markers, inflammation and cytokines, oxidative-stress and antioxidant markers, apoptosis or cell injury

Reported result

Article-reported result excerpt (24 words maximum): “Results: Compared to HRW and CaH_2, OSHCs demonstrated a prolonged reduction in ORP for 60 minutes in vitro and enabled a regulated release of…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.

Extraction completeness

The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.

A reported association, difference or mechanism is not automatically a clinical benefit.

Interpretation limits

Limitations and applicability

Main methodological cautions

Human evidence; design, sample size and comparator limit interpretation. Funding or grant information is reported in the full article. The article declares no conflicts of interest.

Applies directly to

Applies only to the population and protocol reported in this oral and dental health article.

No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.

Sources and status

Sources and record status

Identifiers

PMID: 39310256 · DOI: 10.7150/ijms.101114

Publisher access

A free full article is available through PubMed Central.

Extraction basis

Official PubMed/PMC full article; record re-audited and corrected 25 August 2026.

Last reviewed

25 August 2026

Help the next reader

Help people check the facts before they buy.

Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.

Support independent access
Help us correct the recordReport a discrepancy

Send the exact difference between this page and the linked source. The study reference is attached automatically.